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Dual Relief of T-lymphocyte Proliferation and Effector 
Function Underlies Response to PD-1 Blockade in 
Epithelial Malignancies 
Camille Charlotte Balança1, Clara Maria Scarlata1, Marie Michelas1, Christel Devaud1. Victor Sarradin 1•2, 
Camille Franchet3 .4, Carlos Marti nez Gomez1 •5, Carlos Gomez Roca1.2, Marie Tosolini6, Diana Heaugwane7, 
Françoise Lauzéral Vizcaino1 .4, Lucile Mir Mesnier8, Virginie Féliu1, Carine Valle6, Frédéric Pont6 , 
Gwénaël Ferron5, Laurence Gladieff, Stéphanie Motton9, Yann Tanguy Le Gac9, Agnès Dupret Bories5, 
Jérôme Sarini5, Benjamin Vaire19, Claire lllac7, Aurore Siegfried Vergnon3, Eliane Mery7, 
Jean Jacques Fournié1, Sébastien Vergez4•9, Jean Pierre Delord1 .2.4, Philippe Rochaix7, 
Alejandra Martinez1 •5, and Maha Ayyoub1 .4 .s
Although understanding of T cell exhaustion is widely based on 
mouse models, its analysis in patients with cancer could provide 
clues indicating tumor sensitivity to immune checkpoint blockade 
(ICB). Data suggest a role for costimulatory pathways, particularly 
CD28, in exhausted T cell responsiveness to PD 1/PD L1 blockade. 
Here, we used single cell transcriptomic, phenotypic, and function 
al approaches to dissect the relation between cos+ T cell exhaus 
tion, CD28 costimulation, and tumor specificity in head and neck, 
cervical, and ovarian cancers. We found that memory tumor 
specific cos+ T cells, but not bystander cells, sequentially express 
immune checkpoints once they infiltrate tumors, leading, in situ, to 
a functionally exhausted population. Exhausted T cells were none 
Introduction 
cos+ T cells targeting cancer antigens infiltrate tumors, and the 
extent of the cos+ T cell infiltra te correlates with better prognosis (1 ). 
Nonetheless, expression of inhibitory immune checkpoints (IC), such 
as PD 1, CTLA 4, TIGIT, and TIM 3, in tumor infiltrating cos+ 
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theless endowed with effector and tumor residency potential but 
exhibited loss of the costimulatory receptor CD28 in comparison 
with their circulating memory counterparts. Accordingly, PD 1 
inhibition improved proliferation of circulating tumor specific 
cos+ T cells and reversed functional exhaustion of specific T cells 
at tumor sites. In agreement with their tumor specificity, high 
infiltration of tumors by exhausted cells was predictive of 
response to therapy and survival in ICB treated patients with 
head and neck cancer. Our results showed that PD 1 blockade 
mediated proliferation/reinvigoration of circulating memory 
T cells and local reversion of exhaustion occur concurrently to 
control tumors. 
T cells contributes to their functional exhaustion (2, 3). Therapeutic 
blockade of !Cs is effective in the treatment of cancers of different 
histologie types. However, even in responsive malignancies, not ail 
treated patients experience meaningful clinical responses (2). Under 
standing mechanisms of exhaustion and, consequently, those of 
response to immune checkpoint blockade (ICB) is necessary for the 
clinical development of next generation immunotherapies and the 
identification of biomarkers of response. 
Through analysis of transcriptomic and epigenetic profiles in 
murine models of chronic viral infection or cancer, a picture has 
emer:ged whereby exhausted T cells could represent a cos+ T cell 
lineage distinct from effector or memory cells ( 4 6). Tissue resident 
memory T (Trm) cells represent, likewise, a distinct lineage of cells 
emer:ging during immune responses to infection (7 9). These cells 
reside in tissues, are maintained regardless of antigen persistence, and 
ensure protection upon local reencounter with infectious agents. In 
patients with cancer, cos+ T cells expressing Trm markers have been 
identified ( 10, 11) and seem to over lap with exhausted T cells at tumor 
sites. It remains unclear, however, whether these cells represent, as in 
murine models of infection, cos+ T cell lineages or a functional state 
acquired at tumor sites. 
!Cs can limit T cell priming and expansion by interfering with
CD28 mediated costimulation and can control effector functions 
through the impairment of T cell receptor (TCR) complex signal 
ing (2, 12). PD 1 engagement leads to dephosphorylation of molecules 
in the TCR complex signaling pathway (13, 14), and studies have 
challenged this dogma and propose CD28 as the main target of 
PD 1 (15 17). These findin� may seem at odds with the distribution 
of PD 1 ligands, in particular PD L1 expressed at effector sites (18), 
(between 2 4 mm), and dissociated using C Tubes (Miltenyi Biotec)
and the gentleMACS Octo Dissociator (Program MultiC01 01;
Miltenyi Biotec) in Iscove's Modified Dulbecco's Medium (IMDM,
Sigma Aldrich). PBMCs and tumor single cell suspensions were
cryopreserved in FBS (Gibco) containing 10% DMSO (Sigma
Aldrich).
Pretreatment tumor biopsies used for IHC analyses were obtained
from a second cohort of patients with head and neck squamous cell
carcinoma receiving ICB therapy with PD 1/PD L1 blocking agents
(nivolumab, n 21; pembrolizumab, n 1; durvalumab, n 7; and
avelumab, n 1) to treat locally advanced or metastatic disease.
Biopsies were either obtained up to 2 months prior to the first ICB
dosing (5 patients) or retrieved from archival samples (25 patients: <1
year, 8 patients; ≥1 year and <2 years, 9 patients; ≥2 years and <3 years,
4 patients; and ≥3 years and <5 years, 4 patients). Samples were
handled by the Biopathological Support Platform for Clinical Studies,
IUCT O. Response to therapy was evaluated by iRECIST criteria.
Progressive disease (PD) was defined as the increase of >20% of
target lesions or appearance and increase in size of new lesions in at
least two CT scan evaluations performed at least 4 weeks apart. Partial
response (PR) was defined as a decrease of >30% in target lesions
and complete response (CR) as disappearance of target and non
target lesions, both in at least two CT scans performed at least
4 weeks apart. Any response other than PD or PR/CR was con
sidered as stable disease (SD).
Cell purification and phenotypic assessment
CD8þ T cells were enriched from PBMCs or tumor single cell
suspensions by positive magnetic selection (CD8MicroBeads, human,
Miltenyi Biotec) using OctoMACS Separator and MS Columns
(Miltenyi Biotec). Cells (0.5 to 1  106 CD8þ T cells for PBMCs and
0.1 to 0.5 106 CD8þT cells for TILs) were assessed phenotypically by
staining with mAbs specific for CD3, CD4, CD8, CD45RA, CCR7,
PD 1, TIGIT, TIM 3, CD28, CD103, CD69, CD49a, and CD39, as
indicated, in PBS containing 5% FBS, for 15 minutes at 4C. For
intracellular and intranuclear staining, cells were fixed and
permeabilized with fixation/permeabilization buffer for 45 minutes
at 4C, and stained in permeabilization buffer for 45 minutes at 4C
with mAbs specific for CTLA 4, granzyme B, perforin, TCF 1,
and TOX using the Foxp3/Transcription Factor Staining Buffer Set
(eBioscience). Antibodies used are listed in Supplementary Table S1.
Where indicated, CD8þ T cells were stained with HLA class I
dextramers containing NY ESO 1 Peptides (Immudex) or pentamers
containing CMV or EBV Peptides (ProImmune) for 30 minutes at
room temperature prior to phenotypic assessment (see Supplementary
Table S2 for the complete listing of multimers). Cells were analyzed
using BD LSRFortessa X20, and data were analyzed using DIVA
Software (BD Biosciences) or the vi SNE Algorithm (Cytobank, Inc.).
In vitro differentiation of naïve CD8þ T cells
Naïve CD8þ T cells were enriched from PBMCs either by magnetic
selection (Naïve CD8þ T Cell Isolation Kit, human, Miltenyi Biotec)
using QuadroMACS Separator and LS Columns (Miltenyi Biotec) or
by total CD8þ T cell positive magnetic selection (CD8 MicroBeads,
human, QuadroMACS Separator, LS Columns) followed by staining
with mAbs specific for CD8, CD45RA, CCR7, and CD28, and naïve
(CD45RAþCCR7þCD28þ) CD8þ T cells were sorted via FACS (BD
FACSAria Fusion). Antibodies are listed in Supplementary Table S1.
Cells were then labeled with CFSE (5 mmol/L; eBioscience), stimulated
with anti CD3/28 beads (Miltenyi Biotec) at a bead to cell ratio of 1:1,
and maintained in culture in the presence of recombinant human (rh)
and with the correlation of PD L1 expression at tumor sites to response 
to PD 1/PD L1 blockade (19). Precise assessment of PD 1 and CD28 
expression in tumor specific CD8þ T cells could contribute to the 
clarification of the relative contribution of ICB mediated PD 1 inhib 
itory signal relief on expansion and effector functions of tumor specific 
T cells.
Here, in ovarian, cervical, and head and neck cancers, three 
epithelial malignancies exhibiting resistance to ICB, we characterized 
exhaustion in tumor antigen specific CD8þ T cells. We showed that 
along with chronic stimulation of tumor specific T cells, IC expression 
was sequentially acquired, leading to a population expressing the four 
checkpoints PD 1, TIGIT, CTLA 4, and TIM 3, which we called 
quadruple positive (QP). Incremental checkpoint expression was 
accompanied by increased expression of Trm markers (8, 9), ectonu 
cleotidase CD39 (20), and transcription factor TOX (21), and QP cells 
exhibited significant loss of CD28. QP cells were endowed with high 
cytotoxic potential. Circulating cancer antigen specific T cells had a 
memory phenotype and expressed PD 1 and TIGIT only. At the tumor 
site, specific CD8þ T cells acquired an exhausted Trm like phenotype. 
Circulating specific PD 1intCD28þ T cells responded to anti PD 1 by 
enhancing their proliferation in response to antigen stimulation, 
and specific PD 1hiCD28þ/ tumor infiltrating lymphocytes (TIL) 
exhibited reversal of their functional exhaustion. QP cells were 
predictive of response to therapy and overall survival (OS) in patients 
with head and neck cancer treated by PD 1/PD L1 blockade therapy. 
Our results show that the combination of proliferation/reinvigoration 
of circulating memory T cells that could replenish the tumor site 
combined with reversal of exhaustion at the tumor site contributes to 
PD 1/PD L1 blockade mediated tumor control.
Materials and Methods
Patient and healthy donor samples
Peripheral blood and tumor samples were collected from patients 
with head and neck, ovarian, and cervical cancer at the time of surgery 
for primary disease (54 patients) or for recurrence (1 patient) at the 
Institut Universitaire du Cancer de Toulouse Oncopole (IUCT O, 
Toulouse, France) in accordance to the Declaration of Helsinki, upon 
approval by the institutional review board (nDC 2016 2656) and 
written informed consent. The study included: patients with stage 
FIGO IB1 IIIB HPV 16þ and/or 18þ cervical cancer with squamous 
and adenocarcinoma histology. Patients with stage FIGO IIIB IVA 
high grade serous or clear cell (1 patient) ovarian cancer and locally 
advanced, recurrent or metastatic head and neck squamous carcino 
ma. All patients had histologically documented tumors, were ≥18 years 
old at the time of study entry, were followed within a standard of care 
procedure, and had an Eastern Cooperative Oncology Group perfor 
mance status of 0 2. Exclusion criteria included: known history of a 
positive test for hepatitis B, hepatitis C, human immunodeficiency, or 
hantaviruses; any condition contraindicated with blood sampling 
procedures; pregnancy or breast feeding; and active, suspected, or 
prior documented autoimmune disease or use of immunosuppressive 
medication. Patients did not receive any therapy during the 3 months 
prior to study entry. Blood samples from 14 healthy donors were 
obtained from the Etablissement Français du Sang.
Plasma was harvested after heparinized whole blood centrifugation 
at room temperature. Peripheral blood mononuclear cells (PBMC) 
were isolated by density gradient sedimentation using Ficoll Hypaque 
(Sigma Aldrich). Tumor samples were rapidly transported to the 
research facility on ice. On arrival, samples were rinsed with PBS 
(Sigma Aldrich), subsequently minced on ice to smaller pieces
com/site/fredsoftwares/products/single cell virtual cytometer) using
the sum of CD3D, CD3E, and CD3G gene expression and CD8B gene
expression. Wilcoxon P values for differentially expressed genes were
adjusted with Benjamini Hochberg and illustrated in a volcano plot.
The maturation trajectories of the selected T cells were computed with
FateID as described previously (24), specifying CD8þ T cells in cluster
5 (Fig. 3A) as an endpoint. The gene set enrichment analysis of the
coexpression nodes, here, taken as lists of genes, were computed with
Autocompare ZE (https://sites.google.com/site/fredsoftwares/products/
autocompare ze) for enrichment for gene sets from the C5 collection of
geneontology (GO)database (GSEA/MSigDBdatabase, v6.3; refs. 25 27).
ScRNA seq data have been deposited in NCBI's Gene Expression Omni
bus (GEO; ref. 28) and are accessible through GEO series accession
number GSE148162.
T-cell functional assessment
CD8þ T cells isolated from tumor single cell suspensions were
stimulated with phorbol 12 myristate 13 acetate (PMA, 100 ng/mL;
Sigma Aldrich) and ionomycin (1 mg/mL; Sigma Aldrich) or
plate bound anti CD3 (1 mg/mL; eBioscience) in the presence of
anti CD107a (Supplementary Table S1) for 6 hours in IMDM
supplemented as described above. Brefeldin A (10 mg/mL; Sig
ma Aldrich) was added 1 hour after the beginning of the incuba
tion. Cells were then stained with mAbs, as described above, specific
for CD3, CD4, CD8, and PD 1, and cytokine production was
assessed by intracellular staining using IFNg and TNFa specific
mAbs (Supplementary Table S1). The cells were analyzed by flow
cytometry (BD LSRFortessa X20).
For the assessment of NY ESO 1 specific cells, CD8þ T cells were
magnetically sorted from PBMCs and tumor single cell suspensions,
as already described, from patients with ovarian cancer exhibiting
antibody responses to NY ESO 1. Antibody responses to NY ESO 1
were assessed in patient plasma by ELISA, as described previously (29)
and detailed hereafter. Eighteen overlapping 20 to 24 amino acid long
peptides encompassing the full lengthNY ESO 1 sequence (25 mg/mL
each in PBS; Peptide 2.0 Inc) were coated on Nunc MaxiSorp Flat
Bottom ELISA Plates (Thermo Fisher Scientific) overnight at 4C.
Plates were then washed with PBS, 0.005% Tween (Sigma Aldrich),
incubated for 2 hours at 37Cwith blocking buffer (PBS, 2% BSA), and
washed with PBS, 0.005% Tween. Plasma (diluted 1/100 in blocking
buffer) was incubated for 2 hours at room temperature and washed
using the same buffer. Plates were then incubated for 1 hour at
room temperature with goat anti human IgG secondary antibodies
(Sigma Aldrich; 1 mg/mL in blocking buffer) and washed. ELISA was
developed using the Alkaline Phosphatase Yellow (pNPP) Liquid
Substrate System for ELISA (Sigma Aldrich). Isolated CD8þ T cells
(20,000 to 150,000 CD8þ T cells from TILs and 2 to 5  105 CD8þ
T cells from PBMCs, per well) were stimulated with NY ESO 1
peptides (1 mmol/L; Peptide 2.0 Inc) in the presence of autologous
CD14þ cells sorted from PBMCs by positive magnetic selection (CD14
MicroBeads, human, OctoMACS Separator andMS Columns, Miltenyi
Biotec) at a 1.5 to 1CD14þ to CD8þ cell ratio, and rhIL2 (50 IU/mL) in
the absence or presence of PD 1 blocking mAb (10 mg/mL) in IMDM
supplemented as above. Day 5 7 cultures were either stained with HLA
class I dextramers containingNY ESO 1 peptides andwith anti CD8 or
stimulated or not with NY ESO 1 peptides (1 mmol/L) and assessed for
IFNg and TNFa production by intracellular staining, as detailed above.
Quantitative multiplex IHC
Sequential chromogenic IHC was performed on 4 mm thick tumor
tissue sections based on the protocol described by Glass and colleagues
IL2 (50 IU/mL; Miltenyi Biotec) and in the presence or absence of 
TGFb (50 ng/mL; PeproTech) in IMDM (Sigma Aldrich) supplemen 
ted with 1% penicillin streptomycin Solution (Sigma Aldrich), 1%
MEM Nonessential Amino Acids Solution (Invitrogen), L Glutamine 
(2 mmol/L, Invitrogen), and 10% human serum (Institut de Bio 
technologies Jacques Boy). On day 7, cells were stained with CD3 , 
CD8 , CD45RA , CCR7 , and CD28 specific mAbs (Supplementary 
Table S1) and analyzed by flow cytometry, as described above. In some 
experiments CD28 cells were sorted from day 7 TGFb cultures via 
FACS (BD FACSMelody), restimulated with anti CD3/28 beads 
(bead to cell ratio of 1:1) in the presence of rhIL2 (50 IU/mL) 
and in absence or presence of blocking PD 1 mAbs (10 mg/mL; 
Bristol Myers Squibb), and assessed 7 days later for CD28 expression 
by flow cytometry.
Droplet-based single-cell RNA-sequencing and single-cell gene 
expression analysis
Tumors, minced as detailed above, were transferred into digestion 
medium (Tumor Dissociation Kit, human, Miltenyi Biotec) and 
dissociated using C tubes and gentleMACS Octo Dissociator (Pro 
gram h TDK3, 37C, Miltenyi Biotec). Samples were filtered using a 
40 mm Nylon Mesh (BD Biosciences). Cell suspensions were then 
centrifuged at 300  g at 4C for 7 minutes, the supernatant was 
discarded. Cell pellets were resuspended in 1 mL Red Blood Cell Lysis 
Buffer (Miltenyi Biotec), incubated for 10 minutes at 4C, centrifuged, 
and the pellets were resuspended in PBS containing 0.04% BSA 
(Euromedex). CD45þ cells were enriched by positive magnetic selec 
tion from single cell suspensions (CD45 MicroBeads, human, Octo 
MACS Separator, MS Columns, Miltenyi Biotec), and cells were 
counted to determine the proportion of live cells. Only samples 
containing >90% live cells were used for single cell RNA 
sequencing (scRNA seq) experiments. CD45þ cells (2 to 4 105 cells) 
were stained with barcoded TotalSeq A mAb (BioLegend).
Single cell libraries (30 gene expression and antibody derived tag 
fractions) were generated using the Chromium Controller Instrument 
and Chromium Single Cell 30 Library and Gel Bead Kit v3 according to 
the manufacturer's protocol (10 Genomics) with some modifications 
as described previously (22). To detect barcoded TotalSeq A anti 
bodies, an ADT library was constructed as previously described for 
CITE seq (22). Single cell library size and quality were confirmed on 
Fragment Analyzer (Agilent). KAPA Quantification Kit for Illumina 
platforms (Kapa Biosystems, Roche) was used to quantify library. 
Samples were pooled in equimolar fashion with desired proportions 
for the two library types (cDNA library fraction at 90% and ADT 
library at 10%). The libraries were sequenced on a NextSeq 550 
(Illumina) in pair end sequencing 28 bp (read1)  91 bp (read2) and 
a single index 8 bp in length. Raw data (FastQ files) for expression and 
antibody detection were computed with CellRanger 3.0 and the 
GRCh38 transcriptome as reference (https://support.10xgenomics. 
com/single cell gene expression/software/pipelines/latest/using/count). 
Data were then loaded in an R session with the Seurat 3.0 toolkit 
package involving the normalization and variance stabilization pack 
age sctransform (23). Samples were individually filtered using unique 
molecular identifier (<300000) and percentage of mitochondrial genes 
(<0.25%) criteria. Using Seurat, datasets were reduced by principal 
component analysis using the 11 first principal components to reduce 
dimensionality by t distributed stochastic neighbor embedding (t 
SNE). A resolution parameter set the granularity at 1.2 for the 
clustering by the K nearest neighbor graph based clustering approach 
of Seurat's FindClusters function. CD8þ T lymphocytes were selected 
using Single Cell Virtual Cytometer software (https://sites.google.
(Supplementary Table S1) and flow cytometry analyses were per
formed as described above for human samples.
Statistical analyses
Normality was assessed using the Shapiro Wilk test. For normally
distributed values, the t test was used for paired or unpaired data.
When the values were not normally distributed, the comparison of
variables was performed with Wilcoxon or Mann Whitney test for
paired and unpaired data, respectively. Lines and error bars in scatter
plots represent mean SD. For correlations, Pearson test was used to
compare variables. For OS analyses, ICB treated patients were sub
divided into two groups according to high (≥median) and low
(<median) tumor infiltration by CD8þ T cells or TIM 3þCD8þ
T cells, Kaplan Meier curves were plotted, and P values determined
by log rank test. Results of statistical analyses are annotated as
follows in figures: ns, not significant (P ≥ 0.05); , P < 0.05;
, P < 0.01; , P < 0.001; , P < 0.0001. All analyses were
performed with GraphPad Prism 7 software.
Results
IC expression defines six tumor-infiltrating CD8þ T-cell
populations
We assessed ex vivo CD8þ ovarian, cervical, and head and neck
cancer (HNC) TILs for PD 1, TIGIT, CTLA 4, and TIM 3. Each of the
four checkpoints was expressed in the three tumor types (Fig. 1A;
Supplementary Fig. S1A). PD 1 was on average expressed in a higher
proportion of cells, followed by TIGIT, CTLA 4, and TIM 3. Although
TIGIT could be expressed both independently and alongside PD 1
(Supplementary Fig. S1A, left contour plots), CTLA 4 and TIM 3
expression appeared systematically associated to that of PD 1 (Sup
plementary Fig. S1A, center and right contour plots, respectively). This
was supported by correlation analyses, which revealed significant
positive correlation between the proportion of PD 1 expressing cells
and those expressing CTLA 4 and TIM 3 but not TIGIT (Supple
mentary Fig. S1B). We then analyzed CTLA 4 and TIM 3 expression
in cells expressing or not PD 1 and TIGIT (Fig. 1B). The majority
of PD 1TIGIT cells did not express CTLA 4 and TIM 3,
which we named “quadruple negative” (QN). PD 1þTIGIT and
PD 1TIGITþ cells did not express CTLA 4 and TIM 3. We named
these cells “PD 1 single” (PD 1s) and “TIGIT single” (TIGITs),
respectively. PD 1þTIGITþ cells could be divided into three popula
tions according to CTLA 4 and TIM 3 expression: (i) expressed
neither CTLA 4 nor TIM 3; (ii) expressed CTLA 4 only; and (iii)
expressed both, called “double positive” (DP), “triple positive” (TP),
and “quadruple positive” (QP), respectively (Fig. 1B). Among the
16 possible coexpression profiles (Fig. 1B, bottom), the six populations
described above were the most frequently and consistently detected in
the three tumor types. The QP population showed the highest inter
individual variation (range 0.7% 62%, median 20.69%). Similar anal
yses from circulating memory/effector CD8þ T cells from healthy
individuals and patients with cancer showed that only QN, PD 1s,
TIGITs, andDPpopulationswere detectable, implying that acquisition
of CTLA 4 and TIM 3 expression takes place in situ (Supplementary
Fig. S2).
In CD8þ TILs, we found that cells expressing both PD 1 and TIGIT
exhibited higher staining intensity for both markers compared with
cells expressing each alone (Fig. 1B; Supplementary Fig. S1A, left
contour plots). Analysis of mean fluorescence intensity (MFI) showed
that PD 1 MFI incrementally and significantly increased in parallel to
the number of expressed ICs in each PD 1þ population (Fig. 1C, left).
with some modifications (30) using mAbs listed in Supplementary 
Table S3. Briefly, slides were dewaxed, subjected to heat mediated 
antigen retrieval (Target Retrieval Buffer pH9 K800021 2, Dako 
Agilent), and immunostained using 3 amino 9 ethylcarbazole 
(AEC, Dako Agilent) as chromogen according to the manufacturer's 
recommendations. To preserve antigens, slides were then mounted 
with an Aqueous Mounting Medium (Dako Agilent) containing 60%
glycerol, 40% distilled H2O, and 10% (w/w) saturated sucrose H2O 
(584 mmol/L; ref. 30) and scanned using Pannoramic 250 Flash III 
Scanner (3DHISTECH Ltd.). After scanning, AEC and antibodies were 
removed. Slides were unmounted and washed with distilled H2O 
before being discolored with increasing gradients of absolute ethanol 
(70% 90%, Sigma Aldrich) according to the SIMPLE1 method (30), 
and rinsed with distilled H2O. Antibody stripping was performed by 
incubation of slides for 30 minutes at 56C in a freshly prepared 
stripping buffer [1% SDS (w/v, Sigma Aldrich), 0.2 mol/L Tris 
HCl pH 6.8 (CliniScience), and 0.1 mol/L b Mercaptoethanol 
(Sigma Aldrich) in distilled H2O; ref. 31], followed by rinsing with 
distilled H2O for 45 minutes. The entire sequence was repeated for 
each antigen assessed.
For each case, at least one region of interest (ROI) of 5,000  5,000 
pixels (1,200 mm2) was selected and extracted from each of the virtual 
slides using ImageScope (Aperio Leica Biosystems). Extracted images 
were registered using ImageJ “Register Virtual Stack Slices” plugin and 
color deconvoluted using FIJI (1.52n). Nuclei segmentation was per 
formed with ILASTIK software. Cell identification, staining evalua 
tion, and results export in csv format was performed using CellProfiler 
software. Pathologists defined fluorescence value for each cell and each 
marker in the ROI and the positivity thresholds for each marker. These 
thresholds were used for the determination of CD3þCD8þ (CD8þ T 
cells) and CD3þCD8þTIM 3þ (TIM 3þCD8þ T cells) cell proportions 
among all nuclei. The median of CD3þCD8þ and CD3þCD8þTIM 3þ 
cell proportions in all patients was used as cutoff to define high 
(≥median) and low (<median) infiltration for each population.
In vivo experiments
Female C57BL/6 mice, 7 weeks old, were purchased from Janvier 
Labs. Experimental protocols were approved by regional Ethic 
Committee of Toulouse Biological Research Federation (C2EA 
01, FRBT) and by the French Ministry for Higher Education and 
Research. The European directive 2010/63/EU was followed for 
guidelines on animal welfare. TC1 cells expressing the HPV 16 E6 
and E7 proteins were developed in the laboratory of T.C. Wu 
(Department of Pathology, School of Medicine, Johns Hopkins 
University, Baltimore, MD). Cells were cultured in complete 
RPMI1640 Medium (Life Technologies) for 2 6 passages and tested 
negative for Mycoplasma.
When 8 weeks old, mice were anesthetized by intraperitoneal 
injection of anesthetic mix [10 mL/kg; made up of ketamine 
(100 mg/kg) and xylazine (10 mg/kg); Centravet], and implanted in 
the oral cavity (intracheek) with 3  104 TC1 cells suspended in a final 
volume of 10 mL of PBS using a Hamilton syringe and 30G needle. At 
day 10 and 18, mice were sacrificed by intraperitoneal injection of 
anesthetic mix (10 mL/kg), followed by vertebral dislocation. Oral 
tumors were harvested, cut in pieces, and enzymatically digested using 
the Mouse Tumor Dissociation Kit (Miltenyi Biotec), C tubes, and 
gentleMACS Octo Dissociator (program 37C m TDK 1). Digestion 
was followed by filtration through a 70 mm cell strainer. Cells were 
resuspended in PBS containing 2% FBS, anti CD16/CD32 (Supple 
mentary Table S1), and 1:1,000 Fixable Viability Dye Stain 700 (BD 









































































































































































































































PD-1s TIGITs PD-1s TIGITs
Figure 1.
Coexpression of ICs defines six tumor infiltrating CD8þ T cell populations. CD8þ TILs were stained ex vivo with mAbs specific for CD3, CD8, PD 1, TIGIT, CTLA 4,
TIM 3, CD103, CD69, CD49a, and CD39 and analyzed by flow cytometry. A, Proportion of CD8þ TILs expressing PD 1, TIGIT, CTLA 4, or TIM 3 for three malignancies
(ovarian cancer, OC, n¼ 17; cervical cancer, CC, n¼ 12; and HNC, n¼ 15). Nineteen independent experiments. Examples of contour plots are shown in Supplementary
Fig. S1A. B, Representative contour plots showing CD8þ T cell CTLA 4 and TIM 3 expression (top right) from gated PD 1 TIGIT , PD 1þTIGIT , PD 1 TIGITþ, and
PD 1þTIGITþ populations (top left). Data corresponding to the proportion of each of the 16 combinations of IC expression are summarized (numbers of samples are
as in A; bottom). Median proportions, among CD8þ TILs, for six subpopulations () was >5%. C,MFI of PD 1 and TIGIT in PD 1þ and TIGITþ cells, respectively, among
CD8þ TIL subpopulations.D, Proportion of CD103þCD69þ, CD103þCD49aþ, and CD39þ cells among the six CD8þ TIL subpopulations identified in B (ovarian cancer,
n ¼ 5; cervical cancer, n ¼ 2; and HNC, n ¼ 2; five independent experiments). Examples of dot plots and histogram plots are shown in Supplementary Fig. S4.
The Wilcoxon test was used to compare variables (ns, not significant;  , P < 0.01;  , P < 0.001;  , P < 0.0001).
clustering identified 11 clusters (Fig. 3A, top left). Clusters 0, 1, 4, 5,
and 9 showed the highest HAVCR2 (TIM 3) expression (Fig. 3A).
CTLA4 was found in the same clusters as well as in clusters 7 and 3.
Expression of TIGIT was found in most clusters, although it was more
frequent in clusters expressing HAVCR2. PDCD1 (PD 1) was also
detected in most clusters, although the frequency of positive cells was
lower than expected, presumably owing to low levels or low detection
of this specific mRNA. Clusters 1, 4, 5, and 9 contained the highest
proportion of cells exhibiting a QP profile and also contained cells
expressing ITGAE (CD103), ITGA1 (CD49a), and ENTPD1
(CD39; Fig. 3A). We then performed differential mRNA expression
analysis between regrouped clusters 1, 4, 5, and 9 and all other clusters.
We identified 761 genes with higher expression in the QP clusters and
94 with higher expression in the other clusters (Fig. 3B). Genes shown
in green in the volcano plot (Fig. 3B) correspond to markers we had
used to characterize these populations (Fig. 2E), and their expression
(Fig. 3C) confirmed that clusters on the right side of the t SNE plot
were most representative of the QP population.
Consistent with IC expression, QP clusters expressed TOX, which
encodes aDNA binding protein involved in T cell exhaustion (Fig. 3B
and C; ref. 21). Differential analysis identified a clear cytotoxicity
signature in QP clusters, including granzymes A, B, and H (GZMA,
GZMB, and GZMH, respectively), perforin (PRF1), and granulysin
(GNLY; Fig. 3B and C). Twenty one transcription factors were
previously identified as being key for memory CD8þ T cell develop
ment and function (35).Of those, sevenwere differentially expressed in
our analysis with SOX 4 (SOX4), Class E bHLHe40 (BHLHE40),
PRDM1, and RUNX2 being more expressed in the QP clusters and
KLF2, T cell factor 1 (TCF 1, TCF7), and BACH2 in the other clusters
(Fig. 3B andD). Expression of SOX 4 is promoted by TGFb (36) and
induces CXCL13 production by CD4 T cells (37). CXCL13 was more
expressed inQP clusters (Fig. 3B andD). Among transcription factors
that were less expressed in QP clusters, KLF2 has been shown to be
downregulated in Trm cells, leading to downmodulation of S1PR1
expression (7). Differential analysis showed lower S1PR1 expression in
QP clusters (Fig. 3B and D). TCF 1 (TCF7) was also less expressed in
QP clusters. In addition to TCF7 and CD28, other early memory T cell
markers were also less expressed in QP clusters, including CCR7 and
IL7R (Fig. 3B and D). Differential analysis also revealed higher
expression of the chemokine receptor gene CXCR6 in QP clusters
(Fig. 3B and D).
We then computed a pseudotimematuration trajectory anchored by
cluster 5 cells as an endpoint (Fig. 3A). Visualizing gene expression in
cells along this trajectory showed TCF7, IL7R, and CCR7 expression in
cells clustered at early stages of thematuration trajectory, whereas cells
expressing ICs, Trm and cytotoxicity markers, as well as CXCL13 and
CXCR6, clustered at later stages of the trajectory (Fig. 3E). Respective
expression profiles of chronologically ordered cells were then Z score
transformed to reveal putative temporally restricted gene sets. This
identified 21 gene expression nodes, which were then analyzed for
enrichment of signatures from the C5 collection of GO database. This
unveiled the prominence of translational signatures during the earliest
maturation stages (nodes 16 20), followed in the latest stages by
signatures of immune responses (nodes 1 3; Supplementary
Fig. S6). These results revealed that exhausted Trm like QP cells are
the most immunologically active CD8þ T cells at the tumor site.
IC QP CD8þ T cells are tumor-specific and respond to PD-1
inhibition
We next assessed QP cell effector function, antigen specificity, and
response to PD 1 inhibition. Tumor infiltrating CD8þ T cells showed
A similar pattern was observed for TIGIT, although the MFI did not 
vary significantly between the TIGITs and DP populations (Fig. 1C, 
right).
Altogether, these analyses revealed a conserved pattern of IC 
expression in the three tumor types, which defined six CD8þ T cell 
populations. Analysis of PD 1 and TIGIT suggested an increase in 
their expression alongside a possible sequential acquisition of CTLA 4 
followed by TIM 3. In an orthotopic mouse model of HNC, PD 1 MFI 
at the tumor site was, likewise, increased in PD 1þCD8þ T cells 
coexpressing TIM 3 compared with those expressing PD 1 only 
(Supplementary Fig. S3). In further support of the sequential acqui 
sition model, the proportion of PD 1þTIM 3þ cells was higher at day 
18 than day 10 tumors (Supplementary Fig. S3A).
IC acquisition is paralleled by Trm markers and CD39 
expression, and CD28 loss
We assessed the expression of Trm markers, CD103, CD69, and 
CD49a (8), and CD39, also expressed in CD103þCD8þ T cells at tumor 
sites (20), in the six CD8þ T cell populations identified (Fig. 1D; 
Supplementary Fig. S4). Trm markers and CD39 were absent or 
expressed in low proportions in QN and TIGITs populations. Their 
proportions were significantly higher among PD 1s cells versus QN 
cells. Whereas no difference in Trm marker expression was detected 
between PD 1s and DP cells, CD39 expression was significantly higher 
in the DP population. Expression of all markers significantly increased 
within the TP population relative to DP cells and was further increased 
in the QP population. These data further supported the serial acqui 
sition pattern of ICs by CD8þ T cells at the tumor site.
The sequential acquisition of ICs is indicative of sustained T cell 
stimulation and could imply disparities in the differentiation stage 
between cells expressing few or several ICs. Assessment of the differ 
entiation stage of tumor infiltrating CD8þ T cells showed that the 
population was homogenous and mostly composed of effector mem 
ory cells (CD45RACCR7; Fig. 2A). Effector memory cells are 
composed of cells expressing CD28 and cells in a more advanced 
differentiation stage that are CD28 (32). We found that effector 
memory TILs contained a significantly lower proportion of CD28þ 
cells versus circulating effector memory cells (Fig. 2B; Supplementary 
Fig. S5A). The CD28 population at the tumor site was enriched in 
cells expressing the four ICs (Fig. 2C), suggesting loss of CD28 
alongside IC acquisition. Analysis of CD28 expression according to 
IC coexpression profiles defined above showed significant loss in CD28 
expression in the QP population (Fig. 2D; Supplementary Fig. S5B). 
Unsupervised integration of flow cytometry data using vi SNE (33) 
identified a QP population expressing Trm markers and CD39 while 
being CD28 (Fig. 2E).
We sought to identify tumor related factors underlying CD28 loss. 
The QP population was characterized by CD103 and high PD 1 
expression, two features that depend on TGFb signaling (9, 34). We 
found that in vitro stimulation of naïve CD8þ T cells in the presence of 
TGFb led to an enhanced loss of CD28 (Fig. 2F; Supplementary 
Fig. S5C). This was not simply due to progression in the differentiation 
stage as TGFb led to delayed differentiation (Fig. 2G). Loss of CD28 
could not be recovered by PD 1 blockade of stimulated CD28 cells, 
isolated from TGFb cultures (Supplementary Fig. S5D).
ScRNA-seq reveals active immune pathway signatures in
IC-positive CD8þ T cells
To characterize the QP population, we performed scRNA seq of 
total tumor infiltrating CD45þ cells isolated from 2 patients with 
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TGFl3 medlated loss of CD28 ln OP cos+ TILs. A, Expression of CCR7 versus CD4SRA ex vivo ln CDa+ T cells from 1 healthy donor (HD) and 1 patient wlth cervical 
cancer (CC; left). Proportions of na!Ve (N), central memory (CM), effector memory (EM), and effector (E) cos+ T cens are sumrnarlzed (rlght). Healthy donor PBMCs,n 
= 8; patlent(P) PBMCs(ovarlan cancer,n = 12; cervlcal cancer,n = 9; and HNC, n= TI); and TILs(ovarlancancer,n = 17; cervlcalcancer,n = TI; and HNC, n= 9). Twenty 
lndependent experlments. B, Proportion of CD28+ cells among EM cos+ T cells ls sumrnarized. Hlstogram plots are shown ln Supplementary Fig. SSA. Healthy don or 
PBMCs, n = 8; patient PBMCs (ovarlan cancer, n = 13; cervical cancer,n = 9; and HNC, n = TI); and TILs(ovarlan cancer, n = 16; cervical cancer,n = 8; and HNC,n = 7). 
Elghteen lndependentexperlments. C, Expression of CD28 versus PD 1, TIGIT, CTLA 4, and TIM 3 ln cos+ T cells from 1 representatlve ovarlan cancer patlent's TILs. 
D, Proportion of CD28+ cells ln the six cos+ TIL subpopulatlons deflned as ln Fig. 1B. Ovarlan cancer,n = 16; cervical cancer, n = 10; and HNC, n = TI. Ten Inde pendent 
experlments. CD28 stalnlng 1s shown ln Supplementary Fig. SSB. E, t SNE plots of flow cytometry data of cos+ TILs (ovarlan cancer, n = 1; cervical cancer, n = 1; and 
HNC, n = 1). F and G, Na!Ve coa+r cells were sorted from PBMCs of healthy donors (Supplementary Fig. SSC), CFSE labeled, and stlmulated wlth antl CD3/CD28 ln 
the absence ( ) or presence( +) of TGFl3. Day7 cultures werestalned for CD3, CDS, CCR7, CD4SRA ,and CD28 and analyzed by flow cytometry(healthy donors, n= 8; 
three lndependent experlments). F, CD28 versus CFSE stalnlng ln CDa+ T cells for 1 healthy don or (left); the proportion of CD28+ cells 1s summarlzed (rlght). G, CCR7 
versus CD4SRA expression ln CDa+ T cells (left); the proportion of nalve, central memory, and effector memory cens 1s summarlzed for each stimulation condition 
(rlght). P values were calculated uslng Mann Whitney test (B), Wllcoxon test (D-G), and palred t test (F; .. , P < 0.01; .... , P < 0.0001). 
progression in TOX expression along IC acquisition (Fig. 4A and B; 
Supplementary Fig. S7 A and S78). An opposite pattern was observed 
for the expression of TCF 1 (Supplementary Fig. S8A). Absence of 
TCF 1 in late stage populations at the tumor site was in agreement 
with its progressive Joss along differen tiation in circulating CDS+ T 
cells (Supplementary Fig. S88 and S8C). E xpression of granzyme B and 
perforin, inferred from scRNA seq analyses, was also confirmed at the 
protein level. The proportion of cells expressing both proteins was 
higher in the QP population than in other cos+ TILs (Fig. 4A and B). 
This was consistent with their CD28- phenotype indicating advanced 
differentiation (32). 
To validate the effector potential of Q P cells, we stimulated tumor 
infiltrating cos+ T cells with PMNionomycin (i.e., bypassed prox 
imal TCR signaling and IC inhibition). PMA/ionomycin stimulation 
perturbed, in some samples, TIGIT, CTLA 4, and TIM 3 expression 
but not that of PD 1. We, therefore, analyzed cytokine production and 
CD107a surface expression in cos+ populations defined by PD 1 
expression (Fig. 4C). PD 1- cells encompassed the QN and TIGITs 
populations, PD 1m•corresponded to PD ls and DP populations, and 
PD 1 hi represented the TP and QP populations (Fig. 1B and C). Our 
data showed that PD l lù cells were able to release cytotoxic granules 
and produce cytokines (Fig. 4D and E). Compared with the two other 
populations, PD l lù cells encompassed fewer polyfunctional cells, that 
is, able to produce both IFNy and TNFa, and more IFNy�NFa- cells 
(Fig. 4E), a feature that has been associated with exhaustion (38). 
Accordingly, upon anti CD3 instead of PMNionomycin stimulation, 
PD 1 hi cells comprised fewer cytokine producing cells than Jess 
exhausted, PD 1 - and PD l int, populations (Fig. 4F). 
NY ESO l, a cancer testis antigen expressed in ovarian cancer, 
induces both antibody and T cell responses (29). Severa! NY ESO 1 
derived cos+ T cell epitopes are presented by frequently expressed 
HLA class I alleles (39). Within the ovarian cancer cohort, weidentified 
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ScRNA seq reveals cytotoxic and active immune pathway signatures in IC positive CD8 T cells. CD45þ cells isolated ex vivo from twoHNC specimenswere subjected
to scRNA seq. A, t SNE plots of 752 CD8þ T cells (top left) color coded by their associated cluster and t SNE plot color coded for expression (gray to blue) of
HAVCR2, CTLA4, TIGIT, PDCD1, ITGAE, ITGA1, and ENTPD1. B, Differential analysis of scRNA seq data from clusters 1, 4, 5, and 9 versus those from the remaining
clusters. Genes encoding markers used above to characterize CD8þ TILs are shown in green, and part of the new genes identified with significant differential
expression are shown in red.C andD,Violin plots showing the expression of selected genes in the 11 clusters. x axes indicate cluster number. E,FateID heatmapbased
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Figure 4.
IC QP cells retain effector potential. A and B, CD8þ TILs were stained ex vivowith mAbs specific for CD3, CD8, PD 1, TIGIT, CTLA 4, TIM 3, TOX, granzyme B (GrzB),
andperforin (Perf) and analyzedbyflowcytometry.A,Histograms showingTOXexpression (top) anddot plots of granzymeBversus perforin expression (bottom) in
the indicated CD8þ TIL subpopulations. The cutoff for TOX staining was determined on the basis of TOX staining in CD8þ T cells from PBMCs (Supplementary
Fig. S7A).B, Proportion of TOXþ cells (left), MFI of TOX staining in total cells in each population (middle; ovarian cancer, n¼ 4; cervical cancer, n¼ 3; and HNC, n¼ 2;
two independent experiments), andproportion ofGrzBþPerfþ cells (right; ovarian cancer, n¼4; cervical cancer, n¼ 2; HNC, and n¼ 1; four independent experiments)
in CD8þ TIL subpopulations are summarized. CD8þ TILs were stimulated ex vivo with PMA/ionomycin (two independent experiments; C–E) or anti CD3 (two
independent experiments; F) in the presence of anti CD107a and brefeldin A for 6 hours. Cells were then stained for CD3, CD8, PD 1, IFNg , and TNFa and analyzed by
flow cytometry. C, Gating strategy based on PD 1 expression (PD 1neg, green; PD 1int, orange; and PD 1hi, purple; maintained throughout figure). D, Histogram plots
showing surface CD107a expression gated on the indicated populations (left). Proportions of CD107aþ cells in each population are summarized (right; ovarian cancer,
n¼ 5 and HNC, n¼ 1). E, IFNg versus TNFa staining gated on the indicated populations (left). The proportion of total cytokineþ (IFNg and/or TNFa) cells, as well as
those of IFNg single positive and IFNg/TNFa double positive cells among total cytokineþ cells are summarized for each CD8þ TIL subpopulation (right; ovarian
cancer, n¼ 6 and HNC, n¼ 1). F, Proportion of total cytokineþ (IFNg and/or TNFa) cells among each CD8þ TIL subpopulation (cervical cancer, n¼ 2 and HNC, n¼ 4).
P values were determined using the Wilcoxon test (B, %TOXþ and TOX MFI; E) or paired t test (B, %GrzB/Perfþ; F; ns, not significant;  , P < 0.05;  , P < 0.01;
 , P < 0.001).
patients with serologic responses to the antigen, indicative of an
ongoing T cell response (29). We used HLA class I/NY ESO 1 fluo
rescent multimers to detect antigen specific T cells in these patients.
The proportion of antigen specific T cells was higher in CD8þ cells
isolated from TILs than from PBMCs, suggesting that they were
preferentially attracted, proliferated, and/or were retained at tumor
sites (Fig. 5A and B; Supplementary Fig. S9A). Similar proportions of
CD8þ T cells specific for chronic viruses were detected in PBMCs and
TILs (Fig. 5A and B; Supplementary Fig. S9A), further confirming the
specific in situ accumulation of tumor specific T cells. NY ESO 1
specific T cells in the periphery expressed PD 1 and TIGIT, both with
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IC QP cells encompass tumor specific cells and respond to PD 1 inhibition. A and B, CD8þ TILs were stained ex vivowith HLA class I multimers harboring NY ESO 1,
cytomegalovirus (CMV), or Epstein Barr virus (EBV) epitopes and withmAbs specific for CD3, CD8, PD 1, TIGIT, CTLA 4, and TIM 3 and analyzed by flow cytometry.
A, NY ESO 1 multimer (NY ESO 1, top) and CMV multimer (CMV, bottom) staining versus PD 1, TIGIT, CTLA 4, and TIM 3 expression gated on CD8þ T cells from
representative patients with ovarian cancer. NY ESO 1þ cells shown in blue and CMVþ in gray. B, Summary of the proportions of NY ESO 1 [N; PBMC (P), ovarian
cancer, n¼ 6; TIL (T), ovarian cancer, n¼ 8) and CMVor EBV (C/E; PBMC and TIL: ovarian cancer, n¼ 1, HNC, n¼ 1) multimerþ cells among CD8þ T cells isolated from
PBMCs and TILs (top, 13 independent experiments). Examples of staining of circulating CD8þ T cells are shown in Supplementary Fig. S9A. Summary of the
proportions of QN, PD 1s, TIGITs, DP, TP, and QP cells among NY ESO 1 and CMV or EBV multimerþ CD8þ TILs. NY ESO 1þ cells shown in blue (bottom, four
independent experiments). C and E, CD8þ T cells isolated from PBMCs and TILs of NY ESO 1 seropositive patients with ovarian cancer were stimulated in vitrowith
NY ESO 1 peptides and autologous CD14þ cells in the absence ( ) or presence (þ) of blocking anti PD 1.C,Day 5 to 7 cultureswere stainedwith NY ESO 1multimers
and anti CD8 and analyzed by flow cytometry (seven independent experiments). Representative dot plots (left) and the proportion of multimerþ cells among CD8þ
Tcells (right) are shown (top, PBMCs,n¼ 3; bottom, TILs,n¼ 5). Connectedpoints indicate the samepatient sample.D,Day7TIL cultures restimulatedwithNY ESO 1
peptides and tested for IFNg and TNFa production by intracellular cytokine staining (four independent experiments). Representative dot plots (left) and the
proportion of cytokineþ cells among CD8þ T cells in each culture condition (right) are shown (n¼ 5). Connected points indicate the same patient sample. E, Floating
bars (min tomax) represent fold increase in the proportion ofmultimerþ cells (proliferation) and of cytokineþ cells in CD8þ T cells stimulated in presence of anti PD 1
compared with those stimulated in absence of anti PD 1. P values were calculated using Mann Whitney test (B) and unpaired t test (E;  , P < 0.05; , P < 0.001).
tial, and sensitivity to PD 1 blockade supported their contribution to
responsiveness to ICB in vivo, which was inferred by the correlation
between the proportion of exhausted CD8þ TILs and response to
therapy and survival following ICB.
On the basis of murine models of chronic infection, exhausted
T cells are proposed as a lineage of CD8þ T cells distinct frommemory
T cells (4, 5). Our results showed that circulating tumor antigen
specific CD8þ T cells were memory CD28þ cells. These cells, like
nonexhausted memory circulating PD 1þCD8þ T cells from healthy
individuals (40), expressed lower PD 1 compared with their tumor
infiltrating counterparts. Accordingly, circulating tumor specific
T cells, which did not express TIM 3 or CTLA 4, could substantially
expand in vitro upon antigen stimulation, which was enhanced in the
presence of anti PD 1.Murinemodels of exhaustion in cancer, largely
relying on implantable syngeneic tumor cell lines, have quicker
kinetics than human cancers. In one such model, transcription factors
PRDM1 and c MAF are proposed to coordinate a coinhibitory gene
module leading to the concomitant coexpression of several ICs (41).
In agreement with these data, we showed that PRDM1 was more
expressed in exhausted Trm like cells. However, our results argue in
favor of a progressive acquisition of exhaustion with sequential gain of
ICs accompanied by that of Trmmarkers. This is in agreementwith the
model that established degrees of exhaustion severity (21), where the
transcription factor TOX is associated to exhaustion. Our data showed
expression of TOX in QP cells and sequential gain of TOX expression
at the tumor site. A study has shown, in a murine model of chimeric
antigen receptor T cell transfer, that transferred T cells acquire an
exhausted state at the tumor site through TOX and TOX2 dependent
mechanisms (42).
Seminal work shows that CD8þ TILs express Trmmarkers and that
CD103 is involved both in T cell retention at the tumor site and in
tumor recognition (10, 11). Another study shows that the ectonucleo
tidase CD39 is expressed in a subpopulation of CD103þCD8þ T cells
enriched for tumor specificity (20). In agreement with these studies, we
showed that Trm markers and CD39 expression is gained along the
sequential acquisition of ICs and that they had high expression in
antigen specific T cells. We also showed that exhausted cells exhibited
lower S1PR1 expression, consistent with their in situ retention, and
expressed the chemokine receptor CXCR6. CXCR6 is expressed in
liver Trm cells (43), and its ligand, CXCL16, which can be produced in
soluble and membrane bound forms (44), is expressed by tumor cells
of different histologic types and is associated with increased tumor T
cell infiltration (45). We propose that CXCR6 expression in exhausted
Trm like cells facilitates their migration toward and their interaction
with tumor cells.
We showed that TGFb, involved in the induction of CD103 (9) as
well as in high PD 1 expression (34), could also be implicated in CD28
loss. To our knowledge, this is not a function that has been attributed to
TGFb, although it is consistent with its immune suppressive role.
Expression of SOX 4 and CXCL13 in the QP population further
supported the involvement of TGFb in its in situ development. Indeed,
TGFb induces SOX 4 (36, 37), whichmediates CXCL13 production by
CD4þ T cells (37). CXCL13 has been involved in tertiary lymphoid
structure (TLS) induction in inflammatory diseases (37), and its
expression by tumor infiltrating CD8þ T cells associates with high
B cell recruitment and TLSs (46, 47).
PD L1 expression in peripheral tissues and the ability of PD 1
recruited SHP2 to dephosphorylate proteins involved in proximal TCR
signaling implies a central role of PD 1 in blocking functions of effector
T cells (13, 14). Studies show that PD 1 signaling inhibits CD28 more
efficiently comparedwithTCRproximal signalingmolecules (15), and,
(Fig. 5A and B; Supplementary Fig. S9). In contrast, bystander virus 
specific T cells never acquired the QP phenotype at the tumor site 
(Fig. 5A and B; Supplementary Fig. S9). NY ESO 1 specific CD8þ 
TILs were CD103þ and CD39þ (Supplementary Fig. S10A). Altogeth 
er, these data demonstrated that acquisition of the QP phenotype 
results from T cell stimulation in the tumor microenvironment and 
inferred that the QP population is solely composed of tumor specific T  
cells. This is consistent with the high expression of MKI67, encoding 
Ki 67, in QP clusters (Fig. 3B).
Significantly fewer CD28þ cells among NY ESO 1 specific T cells 
from TILs was seen versus PBMCs (Supplementary Fig. S10B). 
Antigen specific T cells were CD28þPD 1int in PBMCs and CD28þ/
PD 1hi at the tumor site. To examine the functional consequences of 
these opposite phenotypes, we stimulated circulating and tumor 
infiltrating CD8þ T cells from NY ESO 1 seropositive patients with 
NY ESO 1 peptides in the absence or presence of blocking PD 1 mAb. 
Whereas PD 1 blockade led to enhanced growth of antigen specific 
T cells from PBMCs, no effect was observed on the proliferation of 
antigen specific T cells from TILs (Fig. 5C). PD 1 inhibition was not, 
however, ineffective at the tumor site, as it led to increased production 
of effector cytokines by antigen specific T cells (Fig. 5D and E).
IC-positive CD8þ T cells predict clinical response to PD-1/PD-L1 
blockade
Using quantitative multiplex IHC (30, 31), we assessed QP cells in 
pretreatment tumor samples from a cohort of 30 patients with 
metastatic or recurrent head and neck squamous cell carcinoma 
treated with ICB targeting the PD 1/PD L1 axis. The proportion of 
CD8þ or QP TILs was then correlated to response to therapy and OS. 
Because TIM 3 was the final checkpoint acquired at the tumor site, we 
used it as a surrogate marker of the QP population. Examples of 
staining obtained in samples exhibiting a high or low TIM 3þCD8þ 
T cell infiltrate are shown in Fig. 6A (top and bottom, respectively). 
Quantification of QP (0.03% 15.98% of all nuclei, median 1.9) and 
total CD8þ (0.15% 23.49% of all nuclei, median 5.57) TILs showed 
that their proportion was variable among patients. A correlation was 
observed between the CD8þ infiltrate and response to therapy, 
although it did not reach statistical significance (Fig. 6B). Infiltration 
by QP cells significantly correlated with response to therapy and OS 
(Fig. 6B and C), whereas the total CD8þ infiltrate did not significantly 
correlate with OS (Fig. 6C). The median survival of patients in the 
high and low CD8þ T cell groups was 12.7 and 8.8 months, respec 
tively. Median survival of patients with low QP infiltrate was 
5.8 months, whereas that of patients with high QP infiltrate was not 
reached. These results corroborate the major contribution of QP cells 
to antitumor immunity.
Discussion
Our results put forward T cell exhaustion as an indicator of 
spontaneous adaptive immune response to tumors and, as such, as a 
biomarker of response to ICB. We showed that exhaustion was 
acquired at the tumor site through the sequential expression of ICs 
solely in tumor antigen specific T cells but not in bystander T cells. 
Specific cells additionally acquire Trm markers and CXCR6, allowing 
for their in situ residency. We also showed that exhausted Trm like 
cells were endowed with high cytotoxic and functional potential but 
have lost, for a large part, CD28 and TCF 1 expression. PD 1 blockade 
could revert functional exhaustion of tumor antigen specific CD8þ 
TILs in vitro, while it enhanced proliferation of their circulating 
accordingly, early proliferation of circulating PD 1þCD28þCD8þ T
cells could be associated to response to ICB in patients with non small
cell lung cancer (16, 17).We showed significant CD28 loss, specifically
in exhausted tumor specificCD8þTILs.However, circulating antigen
specific T cells were mostly CD28þ. Our functional analyses showed
that in vitro PD 1 inhibition differentiallymodulated proliferation and
effector functions in circulating and tumor infiltrating antigen
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IC positive Trm like exhausted CD8 T cells predict response to PD 1/PD L1 blockade and survival in HNC. Proportion of CD8þ T cells and TIM 3þCD8þ T cells were
determined using quantitative multiplex IHC in pretreatment tumor samples from 30 patients with HNC receiving anti PD 1/PD L1 and were correlated to clinical
outcome. A, Representative images showing CD3 (yellow), CD8 (cyan), TIM 3 (magenta), and MNF116 (gray), as well as nuclei (blue) in two representative
tumors with high (patient 30) and low (patient 45) QP infiltrate (left). Zoomed images at 3 magnification (from boxed area in left image) are shown for the
indicated markers (right). B, Frequency of CD8þ T cells (top) and TIM 3þ CD8 T cells (bottom) among all nuclei in patients with PD (n ¼ 16) and patients with
PR (n ¼ 6) or SD (n ¼ 8). C, Kaplan Meier curves of OS by high versus low frequency of total CD8þ T cells (top, cutoff at median ¼ 5.57%) or TIM 3þ CD8þ
T cells (bottom, cutoff at median ¼ 1.9%) among all nucleated cells. P values were determined with the Mann Whitney test (B); comparison of survival curves
was determined with the log rank test (C).
studies (15 17) and could imply that low PD 1 expression in circu
lating antigen specific T cells will preferentially affect CD28 signaling,
whereas overexpression of PD 1 in exhausted Trm like cells allows for
inhibition of TCR signaling in addition to CD28. It is noteworthy that,
in a reconstituted membrane in vitro setting, PD 1 mediated dephos
phorylation of CD28 occurs at low PD 1 densities, whereas TCR
signaling molecule dephosphorylation requires a higher density of
PD 1molecules (15), which could correspond to PD 1 densities found
in PD 1hi exhausted T cells.
Finally, in agreement with their tumor specificity and high
cytotoxic and effector potential, exhausted Trm like T cells were
predictive of response to ICB and survival in a cohort of patients
with HNC. These results may contradict studies suggesting that
TCF 1þCD8þ TILs, termed progenitor exhausted cells, are potential
players in PD 1/PD L1 blockade in vivo efficacy (48 51). However,
these studies largely rely on murine models whereby the degree of
exhaustion attained in few weeks is not necessarily comparable with
that found in patients. One study shows that TCF 1 expression in
tumor antigen specific T cells in patients is detected in only a low
proportion (1%) of circulating antigen specific cells (51). Another
study shows that the proportion of TCF 1þ cells does not correlate
with response to therapy but does correlate with survival in responder
patients only (48). Another report found that the ratio between
TCF 1þ and TCF 1 cells, rather than the proportion of positive
cells, correlates to clinical responses (49). In our study, TCF7 mRNA
and TCF 1 protein were only detected in non QP cells at the tumor
site. Our results showed significant correlation between TIM 3þCD8þ
T cells, which did not express TCF 1, and both response to therapy and
OS following ICB. These results do not exclude a potentially important
role of TCF 1þ tumor specific CD8þ T cells in mediating response to
therapy. We believe that the presence of TIM 3þCD8þ T cells is a
direct indicator, that is, biomarker, of a spontaneous adaptive response
to the tumor that can be mobilized by ICB. Altogether, our results
imply that the combination of proliferation/reinvigoration of circu
lating memory T cells, that will replenish the tumor site, combined to
reversion of exhaustion, even temporary (6), at the tumor site con
tribute to PD 1/PD L1 mediated tumor control.
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